Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.

@article{Park2016EntecavirPT,
  title={Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study.},
  author={Jun Yong Park and Chang Wook Kim and Si Hyun Bae and Kyu Sik Jung and Hee Yeon Kim and Seung Kew Yoon and Kwang Hyub Han and Sang Hoon Ahn},
  journal={Liver international : official journal of the International Association for the Study of the Liver},
  year={2016},
  volume={36 8},
  pages={1108-15}
}
BACKGROUND & AIMS Sequential therapy posed a high risk of emergence of multidrug resistance and presented a management issue in chronic hepatitis B (CHB) treatment. We evaluated the antiviral efficacy and safety of entecavir (ETV) plus tenofovir (TDF) combination therapy in multidrug-resistant (MDR) CHB patients. METHODS In this prospective, multicentre study, MDR CHB patients, defined as measurable serum HBV DNA (≥60 IU/ml) while on any rescue treatment regimen for at least 24 weeks and the… CONTINUE READING